Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

157.32
-6.9500-4.23%
Volume:471.30K
Turnover:75.00M
Market Cap:8.05B
PE:-42.75
High:163.89
Open:163.89
Low:155.56
Close:164.27
52wk High:191.50
52wk Low:86.99
Shares:51.15M
Float Shares:41.87M
Volume Ratio:0.84
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6800
EPS(LYR):-3.6821
ROE:-252.11%
ROA:-16.81%
PB:91.14
PE(LYR):-42.72

Loading ...

Axsome Therapeutics Shares Down 3.5% After Q4 Results

THOMSON REUTERS
·
Feb 23

Stock Track | Axsome Therapeutics Plummets 5.83% Intraday Despite Earnings Beat as High Operating Expenses Concern Investors

Stock Track
·
Feb 23

Axsome Therapeutics: Buy Rating on Solid Execution, Sufficient Cash Runway, and Advancing Late‑Stage Pipeline

TIPRANKS
·
Feb 23

Shares of Axsome Therapeutics Down 2.1% Premarket After Q4 Results

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics reports Q4 EPS (56c), consensus (73c)

TIPRANKS
·
Feb 23

Axsome Therapeutics sees cash runway into cash flow positivity

TIPRANKS
·
Feb 23

Axsome Therapeutics Q4 EPS $(0.56) Beats $(0.68) Estimate, Sales $195.999M Beat $193.107M Estimate

Benzinga
·
Feb 23

Earnings Flash (AXSM) Axsome Therapeutics Posts Q4 Net Loss $0.56 a Share, vs. FactSet Est of $0.71 Loss

MT Newswires Live
·
Feb 23

Axsome posts FY 2025 AUVELITY net product sales of USD 507.1 million, up 74%

Reuters
·
Feb 23

BRIEF-Axsome Therapeutics Q4 Net Income USD -28.559 Million

Reuters
·
Feb 23

Axsome Therapeutics Q4 EPS USD -0.56

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics Q4 Pretax Profit USD -28.129 Million

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics Q4 Revenue USD 195.999 Million VS. Ibes Estimate USD 193.1 Million

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Feb 23

Mizuho Adjusts Price Target on Axsome Therapeutics to $230 From $217, Maintains Outperform Rating

MT Newswires Live
·
Feb 19

Analysts Are Bullish on These Healthcare Stocks: Demant (WILLF), Axsome Therapeutics (AXSM)

TIPRANKS
·
Feb 19

Axsome Therapeutics: Strengthened Sunosi Exclusivity and Robust Late‑Stage Pipeline Underpin Buy Rating

TIPRANKS
·
Feb 18

BRIEF-Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Alkem Laboratories Ltd.

Reuters
·
Feb 17

Axsome Therapeutics Settles SUNOSI Patent Litigation with Alkem

Reuters
·
Feb 17

Axsome Therapeutics Inc - Patent Litigation Against Another Party Related to Sunosi Pending

THOMSON REUTERS
·
Feb 17